Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is APBI appropriate for patients with rare tumor histology (mucinous, medullary, or tubular) if they meet all other suitability criteria?
Answer from: Radiation Oncologist at Community Practice
If phenotype right then it is tubular and mutinous are ER positive low grade tumor and are good candidates for APBI.
Comments
Radiation Oncologist at Allegheny Health Network, Pittsburgh
Agreed, these patients are good candidates for APB...
Radiation Oncologist at Mallory Radiotherapy, PLLC
Hi, thanks for your replies! I asked this question...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Medullary is Associated with BRCA 1 mutation and c...
2481
2482
2483
Sign in or Register to read more
7005
Related Questions
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
Is keratosis follicularis (Darier disease) a contraindication to receipt of PMRT?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
Are there additional risks associated with PMRT for a patient with prior lympho-venous bypass surgery?
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
Agreed, these patients are good candidates for APB...
Hi, thanks for your replies! I asked this question...
Medullary is Associated with BRCA 1 mutation and c...